Showing results (401-410 of 488) with videos related to
Sort By:
Pageof 49
Human Pathology|February 10, 2000
Molecular abnormalities associated with secretory carcinomas of the breastA Maitra, F A Tavassoli, J Albores-Saavedra, et al.Genetics|August 5, 2005
Chromosome complement of the fungal plant pathogen Fusarium graminearum based on genetic and physical mapping and cytological observationsL R Gale, J D Bryant, S Calvo, et al.Behavioural Brain Research|October 14, 2020
The motivational valence of methamphetamine relates inversely to subsequent methamphetamine self-administration in female C57BL/6J miceGabriella Shab, Elissa K Fultz, Ariana Page, et al.Brain, Behavior, and Immunity|August 1, 2021
Neuroimmune mechanisms of cognitive impairment in a mouse model of Gulf War illnessJoshua D Bryant, Maheedhar Kodali, Bing Shuai, et al.Annals of the American Thoracic Society|December 8, 2020
Low-Value Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease and the Association with Healthcare Utilization and CostsKevin I Duan, Laura J Spece, Edwin S Wong, et al.Cancer Immunology, Immunotherapy : CII|April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG studyH M Stege, M Haist, S Schultheis, et al.Journal of Medicinal Chemistry|April 30, 2004
Oral bioavailability of a new class of micro-opioid receptor agonists containing 3,6-bis[Dmt-NH(CH(2))(n)]-2(1H)-pyrazinone with central-mediated analgesiaYunden Jinsmaa, Anna Miyazaki, Yoshio Fujita, et al.Journal of Medicinal Chemistry|December 13, 2005
Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonistsTingyou Li, Yoshio Fujita, Kimitaka Shiotani, et al.Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Studies on the structure-activity relationship of 2',6'-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H-Dmt-NH-CH(3)Yoshio Fujita, Yuko Tsuda, Takashi Motoyama, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 14, 2003
Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptorsKabirullah Lutfy, Shoshana Eitan, Camron D Bryant, et al.Pageof 49